Atherosclerosis and proteinase activation

被引：182
作者：
Dollery, CM
Libby, P
机构：
[1] Ctr Cardiovasc Biol & Med, Div Med, Rayne Inst, London WC1E 6JJ, England
[2] Brigham & Womens Hosp, Leducq Transatlantic Network Excellence Atherothr, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Boston, MA 02115 USA
来源：
CARDIOVASCULAR RESEARCH | 2006年 / 69卷 / 03期
关键词：
atherosclerosis; metalloproteinase; plaque; matrix;
D O I：
10.1016/j.cardiores.2005.11.003
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Rapidly accumulating evidence points to the matrix metalloproteinases (MMPs) as major molecular mediators of arterial diseases. Findings from human pathological specimens, animals, and cell and molecular biology implicate matrix metalloproteinases in all stages of atherosclerosis including lesion initiation and progression and ultimately in plaque complication and triggering of thrombosis. The complex interactions within the proteolytic cascade allow multiple levels of control over these functions. This review weighs the evidence for the role of MMPs in arterial biology with particular reference to their activation in the atherosclerotic plaque. (c) 2005 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码：625 / 635
页数：11
相关论文
共 122 条
[11]   Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease [J].
Blankenberg, S ;
Rupprecht, HJ ;
Poirier, O ;
Bickel, C ;
Smieja, M ;
Hafner, G ;
Meyer, J ;
Cambien, F ;
Tiret, L .
CIRCULATION, 2003, 107 (12) :1579-1585
[12]   PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells [J].
Boire, A ;
Covic, L ;
Agarwal, A ;
Jacques, S ;
Sherifl, S ;
Kuliopulos, A .
CELL, 2005, 120 (03) :303-313
[13]   Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent type II apoptotic pathway [J].
Bond, M ;
Murphy, G ;
Bennett, MR ;
Newby, AC ;
Baker, AH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (16) :13787-13795
[14]   In vivo molecular target assessment of matrix metalloproteinase inhibition [J].
Bremer, C ;
Tung, CH ;
Weissleder, R .
NATURE MEDICINE, 2001, 7 (06) :743-748
[15]   Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation [J].
Carmeliet, P ;
Moons, L ;
Lijnen, HR ;
Baes, M ;
Lemaitre, V ;
Tipping, P ;
Drew, A ;
Eeckhout, Y ;
Shapiro, S ;
Lupu, F ;
Collen, D .
NATURE GENETICS, 1997, 17 (04) :439-444
[16]   Emerging roles for cysteine proteases in human biology [J].
Chapman, HA ;
Riese, RJ ;
Shi, GP .
ANNUAL REVIEW OF PHYSIOLOGY, 1997, 59 :63-88
[17]   Near-infrared fluorescent Imaging of matrix metalloproteinase activity after myocardial infarction [J].
Chen, JQ ;
Tung, CH ;
Allport, JR ;
Chen, S ;
Weissleder, R ;
Huang, PL .
CIRCULATION, 2005, 111 (14) :1800-1805
[18]   In vivo imaging of proteolytic activity in atherosclerosis [J].
Chen, JQ ;
Tung, CH ;
Mahmood, U ;
Ntziachristos, V ;
Gyurko, R ;
Fishman, MC ;
Huang, PL ;
Weissleder, R .
CIRCULATION, 2002, 105 (23) :2766-2771
[19]   Matrix metalloproteinase-9 modulation by resident arterial cells is responsible for injury-induced accelerated atherosclerotic plaque development in apolipoprotein E-deficient mice [J].
Choi, ET ;
Collins, ET ;
Marine, LA ;
Uberti, MG ;
Uchida, H ;
Leidenfrost, JE ;
Khan, MF ;
Boc, KP ;
Abendschein, DR ;
Parks, WC .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (05) :1020-1025
[20]   Cancer therapy - Matrix metalloproteinase inhibitors and cancer: Trials and tribulations [J].
Coussens, LM ;
Fingleton, B ;
Matrisian, LM .
SCIENCE, 2002, 295 (5564) :2387-2392
12345678910